Clinical trial
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT): A Single Center, Open, Randomized Controlled Trial.
NCT04619342 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT): A Single Center, Open, Randomized Controlled Trial.
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 30, 2020
- Completion date
- December 31, 2022
- Enrollment
- 98 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma (hcc) with type iii portal vein tumor thrombus (pvtt)